Title: Antiviral activity, pharmacokinetics, and safety of the HIV-1 protease inhibitor TMC310911, coadministered with ritonavir in treatment-naive HIV-1-infected patients
Authors: Stellbrink, Hans-Jürgen ×
Arastéh, Keikawus
Schürmann, Dirk
Stephan, Christoph
Dierynck, Inge
Smyej, Ilham
Hoetelmans, Richard M W
Truyers, Carla
Meyvisch, Paul
Jacquemyn, Bert
Mariën, Kris
Simmen, Kenneth
Verloes, Rene #
Issue Date: Mar-2014
Publisher: Lippincott Williams & Wilkins
Series Title: Journal of Acquired Immune Deficiency Syndromes vol:65 issue:3 pages:283-289
Abstract: TMC310911 is a novel human immunodeficiency virus type-1 (HIV-1) protease inhibitor with broad in vitro antiviral activity. In this phase 2a, open-label, randomized study, the antiviral activity, pharmacokinetics, and safety and tolerability of ritonavir-boosted TMC310911 was assessed.
ISSN: 1525-4135
Publication status: published
KU Leuven publication type: IT
Appears in Collections:Academic Center for General Practice
× corresponding author
# (joint) last author

Files in This Item:

There are no files associated with this item.

Request a copy


All items in Lirias are protected by copyright, with all rights reserved.

© Web of science